NONPROFIT MEMBER: Side-Out Foundation

The Side-Out Foundation is a 501(c)(3) non-profit organization that was established in 2004 to make a significant and identifiable impact on the lives of metastatic breast cancer patients and their families. The organization takes an innovative approach to provide solutions for those specifically with metastatic breast cancer with the goal of becoming a source of hope for all those living with breast cancer in search of answers and treatment options.

Side-Out’s precision medicine research matches patients with treatments and uses the outcome data produced from this to draw conclusions, challenge the foundations of cancer care, and change the trajectory of the disease. The organization’s educational and community-driven programs Dig Pink® and Ambassador Program are built on creating advocacy for the metastatic breast cancer community, engaging a new generation, and funding Side-Out’s revolutionary research. As both a nonprofit and research organization, The Side-Out Foundation and its supporters work for a future where breast cancer isn’t a terminal diagnosis and anyone receiving a breast cancer diagnosis has hope for more tomorrows.

Side-Out Foundation PROGRAMS & RESOURCES


The Side-Out MBC Research Program

For the past 10 years, Side-Out has done groundbreaking clinical research with a focus on precision medicine for people living with metastatic breast cancer. Now that we know that precision medicine can help people living with MBC make informed decisions about their treatment solutions, the logical next step for us is to get this science in the hands of the people who need it.

Link to program
Education & AwarenessResources & InformationResearch

The Side-Out MBC Bioinformatics Portal

The Side-Out MBC Bioinformatics Portal is a novel open-access relational database developed in collaboration George Mason University. This database was created to capture a large array of information from the Side-Out sponsored studies where cutting-edge technologies are used to identify molecular alterations in individual tumors and devise personalized treatments for MBC patients.

Link to program